BiotechTube

cyclophosphamide + CAR T cells

Phase 1Active
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malignant Pleural Mesothelioma (MPM)

Conditions

Malignant Pleural Mesothelioma (MPM)

Trial Timeline

Sep 30, 2020 → Sep 30, 2026

NCT ID
NCT04577326

About cyclophosphamide + CAR T cells

cyclophosphamide + CAR T cells is a phase 1 stage product being developed by Atara Biotherapeutics for Malignant Pleural Mesothelioma (MPM). The current trial status is active. This product is registered under clinical trial identifier NCT04577326. Target conditions include Malignant Pleural Mesothelioma (MPM).

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04577326Phase 1Active

Competing Products

20 competing products in Malignant Pleural Mesothelioma (MPM)

See all competitors
ProductCompanyStageHype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabCSPC Pharmaceutical Group LimitedPhase 1/2
40
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Tadalafil + GemcitabineEli LillyPhase 1
33
Patritumab DeruxtecanDaiichi SankyoPhase 1/2
41
Tivantinib + FOLFOXDaiichi SankyoPhase 1/2
41
DS-1123Daiichi SankyoPhase 1
33
DS-8201aDaiichi SankyoPhase 1
33
DS-5573aDaiichi SankyoPhase 1
33
DS-6051bDaiichi SankyoPhase 1
33
U3-1565Daiichi SankyoPhase 1
33
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue MedicationsDaiichi SankyoPhase 1/2
41
DS-3201b + DS-3201bDaiichi SankyoPhase 1
33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kgDaiichi SankyoPhase 1
33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
41
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
CP-461Astellas PharmaPhase 2
52
enfortumab vedotinAstellas PharmaPhase 1
33
LNF1901 Monoclonal Antibody InjectionSun PharmaceuticalPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
41
Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
77

Other Products from Atara Biotherapeutics

CMV-pp65 CTLsPhase 2
44
EBV-specific T cells (EBV-CTLs)Phase 2
44
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)Phase 1/2
33
ATA188 + PlaceboPhase 1/2
33
WT1-sensitized T cellsPhase 1
25